Free Essay

Merck Case

In: Business and Management

Submitted By mechman823
Words 3826
Pages 16
Conflict and Change
Harvard Case Study
Professor: Robert Lazer PhD
Team: Zerrin Hejazi, Mark Klabonski, Elizabeth Lamb,
Hari Thenneti Pandurangamoorthi, & Hareshkumar Surani

The History of Merck
U.S. sales office opened in and
George Merck,
grandson, was appointed head of the U.S. branch

Jacob Merck opened Merck in Germany



Heinrich E Merck transformed the business and
Merck began manufacturing 1887

Merck merged with
Sharp & Dohme


The renamed company Merck & Co. opens for business 1953


Merck merged with ScheringPlough Corporation and
Organon BioSciences

Pharmaceutical Industry
• The average drug development time is over fifteen years with an average R&D expenditure of $800 million.
• The FDA requires three phases of testing to assess safety and effectiveness. o Test results dictate what is displayed on the drug’s label and how the doctor will prescribe it.
• Follow-up studies (Phase 5) can be performed to assess the drug after market release (Phase 4) and amend the drug label for improved sales.

Pharmaceutical Success
• 1981 to 2001, Merck experienced an upward trend on several industry metrics.
• Their Return on Sales (ROS) for their Human Pharma line peaked at just over 40% in
2001 with an average of 24% .
• The early 1990’s exhibited a downward trend just prior to
Gilmartin assuming the role of

Pharmaceutical Success
• Cumulative Stock Return over the same period had a compound annual growth rate (CAGR) of 45%.
• Again, the early 1990’s exhibited a downward trend, the first in over a decade.

Measures of Success

Merck had the most patents awarded in both the 1980’s and

From 1994-2001, Merck’s patent volume exemplified their scientific edge.

Problem Statement
In 2002, Ray Gilmartin, Merck’s CEO, was under pressure regarding the company's declining stock performance and surfacing concerns about Merck’s ability to respond to competitors’ successful strategies of acquiring drugs and aggressive marketing.
Merck must find a way to increase profits and market share in a competitive and uncertain environment.

Structural Dimensions
• As a large company with strict FDA enforced regulations, Merck was a company with many documented protocols, job descriptions, and policies. • Merck is highly formalized to prevent health and safety hazards.
• Managing several large key departments, specialization is also high in
o The R&D group functioned as the head of the organization dictating science would rule the company. o Manufacturing and Marketing were forced to do their work at the end of the process after being handed a final product.

Organizational Structure (June 1993)
P. Roy Vagelos
Chairman & CEO

SVP Human


J. Jackson
EVP Worldwide
Human Health


Asia/ Africa


Corporate Planning
& Development



Legal/Public Affairs

E. Scolnick
President MRL











Structural Dimensions
Hierarchy of Authority
• In 1985, Roy Vagelos was appointed Chairman and CEO of Merck. E
Scolnick was acting president of MRL and J. Jackson was the EVP of
Worldwide Human Health.
• Vagelos led with the assistance of the “Chairman’s Staff”. o Each person on the board was the sole contact between their department and Vagelos; a very narrow span of control.
• All decisions went up to Vagelos and Scolnick. The science drove all company plans.
• Jackson’s team, the country and regional managers of marketing and sales, despite their responsibility for profit and loss, had no input on board decisions regarding budgeting and resource allocation.

Structural Dimensions
Mechanistic Vs. Organic
• Based on the centralized structure, specialized tasks, formalized rules, vertical communication, and strict hierarchy of authority it is clear that
Merck operates mechanistically. o However, the mechanistic design is unable to fully support the innovative strategies needed to succeed in the pharmaceutical
R&D world and requires a stable environment. Strategy, Organization Design, & Effectiveness
Strategic Intent
• The mission had always been to create the best medicines for people.

“We never try to forget that medicine is for the people. It is not for the profits.
The profits follow, and if we have remembered that, they have never failed to appear.”
- George W. Merck

Strategy, Organization Design, & Effectiveness
Strategic Intent
• MRL’s core strategy was always to develop breakthrough drugs in new therapeutic categories.
• Gilmartin’s team agreed that drug discovery and commercialization was the only competitive strategy after the environmental shift. o They would focus on investing in innovative R&D and sales and marketing through late-stage development.

Strategy, Organization Design, & Effectiveness
Competitive advantage & Core competence
• Merck’s competitive advantage through the 1980s was their reliability based on their core competence of high quality science. o Merck created their own very high internal standard of efficacy and safety. They earned the trust of the FDA, from which they attained 70% approval rates for new drug applications, 20% higher than the industry standard. • The success of MRL created an overconfidence bias that they would be best at making company wide decisions even when pertaining to the market sector and other areas beyond the R&D.

Strategy and Design
Porter’s competitive strategies
• Differentiation o Merck’s goal to create the best medicines led them to success through the 80s. They developed the highest-quality drugs, but did not invest in the extensive advertising. It was as if Merck expected the drugs to sell themselves based on their high quality.
• Low cost leadership o After the Hatch-Waxman act, Merck’s profits and market share were severely diminished when low-cost led generic brands were able to undercut Merck’s prices after eliminating the R&D cost.

Strategy and Design
Miles and Snow - Prospector, Defender, Analyzer, or Reactor
• At the point when the environment began to shift, Merck’s defender strategy let them down. Their high degree of centralization and clear focus on producing reliable, high-quality medicines allowed other companies to enter the market with more aggressive and innovative strategies. • As a company with stakes in both R&D and manufacturing, Merck required a balance between the prospector and defender strategies.
• Their inner dichotomy elicited an analyzer strategy which would be more adaptable to environmental change and emphasize innovation while balancing efficiency and maintaining tight cost control.

Effectiveness Analysis
When Vagelos stepped down, Gilmartin’s Management Committee evaluated their position with a resource and goals based approach.
• Goals based o Return on Sales o Cumulative Stock Return o Sales and Profits Comparisons o Patents Awarded o Net Sales o Years of Exclusivity
• Resource based o R&D Expenditures per Phase

Effectiveness Analysis
They heavily focused on the numerical data and created benchmarks from an exclusively commercial frame of reference.
They agreed that combining expert drug discovery and mass commercialization was the only competitive strategy after the environmental shift.
He directed them to focus on investing in innovative R&D and sales and marketing through late-stage development.

Structural Groupings
Structure Type (Functional, Divisional, Geographical, Matrix, and Hybrids)
• During Vagelos time the company had a combined functional, divisional, and geographical structure. o At the highest level the company had a functional structure. o Worldwide Human Health Marketing and Sales department had responsibilities were broken out into Country and Region based zones and were geographically controlled. o MRL had their own division structure with separate finance, legal, and human resource departments in addition to the core researcher, development, and regulatory functions.

Structural Groupings
Structure Type (Functional, Divisional, Geographical, Matrix, and Hybrids)
• Gilmartin attempted to flatten the company and expanded the seven person “Chairman’s Staff” into the ten person Management Committee with more line responsibility at each level and greater access to resources. Ray Gilmartin
Chairman, President & CEO

D Anstice
President US
Human Health
The Americas

H Lipmanowicz
Human Health
AP and LA

P Wold-Olsen
Human Health

E Scolnick
President MRL
EVP Science
& Technology

P Lofberg
Managed Care

J Lewent

Marketing and Sales

Management Committee

J Preston
Animal Health

RG Douglas
Merck Vaccine
Division (MVD)

S Darien

M McDonald
Legal / Public

Structural Groupings
• Gilmartin replaced Jackson as the EVP of Worldwide Human Health with three other geographically zoned presidents. o These divisions were both functionally divided by therapy area into
Franchise Business Groups, regionally for the international markets, and functionally for finance, legal, and the clinical/medical division.
The remaining departments did not change.
David Anstice
President Human Health
US, Canada & Latin America

Primary &
Care Sales


& Heart Failure

Arthritis &

& Diabetes



Latin America






Structural Deficiency
Symptoms of failing Functional Grouping
• Slow response time
• Poor horizontal coordination
• Fewer companywide innovations
Symptoms of failing Divisional Grouping
• Reduction of the economies of scale
• Worsened cross company coordination

Information Sharing
Effective Coordination, Communication, and Integration
• Vertical information o Hierarchical referral
• Slow decision making under Vagelos o Rules and plans
• The detailed rules and specifications outlined in company manuals under Vagelos, limited creative planning within the marketing department. o Hundred page ‘strategic plans’ detailed little strategy for the marketing teams and enforced specific minutia like regional head counts.

Information Sharing
Effective Coordination, Communication, and Integration
• Vertical information o Rules and plans (cont’d)
• Gilmartin implemented the Product and Cycle Time Excellence
(PACE) process, a best practices protocol for communication introduced to bring effective communication between MRL and marketing. o It created a specific development plan and set of milestones for each new drug. o It instituted a senior-level Product Approval Committee.

Information Sharing
Effective Coordination, Communication, and Integration
• Horizontal information o Information systems
• Under Gilmartin Merck instituted a web-based marketing tool designed as element of PACE. This would work in conjunction with the marketing curriculum designed to increase professionalism and to better link MRL, marketing, and manufacturing.

Information Sharing
Effective Coordination, Communication, and Integration
• Horizontal information o World Business Strategy Teams (WBSTs)
• Introduced in 1995 to manage the therapeutic franchises on a global basis.
• Their main goal was to drive the development and implementation of each franchise’s strategy and integrate all aspects of the product life in one process discussion.
• Composed of 12-15 people from the US Marketing, Worldwide
Marketing, MRL’s Regulatory group, and MRL’s Clinical group.
• They would plan for both positive and negative study outcomes and ideally run the proper interference.

Information Sharing
Effective Coordination, Communication, and Integration
• Horizontal information o World Business Strategy Teams (WBSTs) (cont’d)
• While the WBSTs sped up communication in support of the needs of the company, the implementation was slow.
• The follow through of action plans could not be ensured because
WBST leaders had no actual authority.
• Team members were not the decision makers and would have to take things to a higher level.
• WBST membership was added on to traditional job roles and some viewed it as a sideline task. o Some team members displayed uneven commitments and were not held accountable.

Information Sharing
Effective Coordination, Communication, and Integration
• Horizontal information o World Business Strategy Teams (WBSTs) (cont’d)
• WBSTs seem to need their own structure and power to accomplish their multi-functional responsibilities.

Task Environment
Government sector
• In 1984, the Government approved regulations opening up the pharmaceutical industry to the free market with the Hatch-Waxman act.
• The FDA then began to allow “direct-to-consumer” advertising in the
1990s. This form of advertising was incredibly effective. It has been shown that, when a patient discusses a drug with a doctor, they will get prescribed that drug 60% of the time.
Industry sector
• With the institution of the Hatch-Waxman regulation, many smaller companies began to manufacture generic medicines, making profits off of the costly drug development of Merck and other competitors.

Task Environment
Tech sector
• New technologies allowed small R&D companies to make significant discoveries and sell to larger manufacturing firms. o This ate away at the need for companies to complete research, development, marketing, and manufacturing all in house.
• Product exclusivity periods declined sharply as a result since the wider range of competitors could more easily bring a similar drug to market.
Market sector
• Managed Care Organizations (MCOs) and physicians that restricted the drug numbers and types prescribed to patients.
• MCOs and potential consumers also put pressure on the pharmaceutical companies to differentiate their products with higher standards of testing and studies.

Task Environment
Socio-cultural sector
• The enhanced competition allowed MCOs and potential consumers to demand lower prices. • A simultaneous increase in interest in
‘lifestyle-enhancing’ drugs offered a new and possibly lucrative franchise group.

Changing Environment
• More and more external elements were affecting Merck’s business.
Regulations were changing, technology was advancing, and the market had increasing requirements. Previously prohibitive to small scale businesses, the market now allowed many new companies to enter
Merck’s domain and push them into a highly complex dimension.
• The shifting task environment only seems to be increasing in frequency in the tech age across all industries. These continuing changes through the
90s make the domain unpredictable and unstable.

Changing Environment
The complex and unstable dimensions yield a high-uncertainty environment which would typically solicit an organic design, decentralized decision making, highly differentiated departments, many integrating roles and boundary spanners, and extensive forecasting combined with high-speed response.
Without any specific boundary spanners or an intelligence team,
Merck was not working proactively against the changing environment in a proactive way.

Manufacturing and Service Technologies
Core Technology
• The MRL - R&D departments of Merck represent the core technology. The entire company is set up to support the drugs that MRL create.
• The PACE process ineffectively brought together the three departments responsible for bringing the final product from concept to consumer in a sequential interdependency.
• The complex development and drug release process required reciprocal interdependence or close collaboration back and forth between MRL, marketing, and manufacturing.

Manufacturing and Service Technologies
Variety and Analyzability
• Despite enacting the PACE process, there is high variability and low analyzability of tasks within roles because every drug formulary outcome requires different procedure and most individual situations do not have a specified process.
• Merck’s R&D and marketing are non-routine technologies. A high amount of expertise and training begin to be required of both as Merck intensifies their marketing strategies along with their innovative research. o Non-routine technology also elicits low formalization, low centralization, heavy amounts of training and expertise, in addition to expansive horizontal communication.

Organization Size, Life Cycle, and Decline
Dilemmas of large size
• Economies of scale allow Merck to compete globally and invest in risky
R&D activities.
Formalization stage
• Merck is creating more procedures and control systems.
• Communication is stilted by the hierarchy and Merck’s size.
• Merck needs to open communication, invite innovation, and develop better collaboration between all departments.
The level of bureaucracy impeded Merck’s ability to function effectively within the changing environment.

Perception and Individual Decision Making
• Merck organization uses the Bounded rationality decision making process: o Define the problem o Identify the decision tree o Allocate weights to criteria o Develop the alternatives o Evaluate the alternatives o Select the best alternative
• Overconfidence bias was present because most employees in leadership positions were highly educated scientists.

Leadership Styles
Dr. Roy Vagelos leadership can be classified as a Transactional
Leadership style. This leadership style was not compatible with implementing changes quickly:
• Contingent Reward
• Active Management by Exception
• Passive Management by Exception
• Laissez-Faire

Bases of Power: Mostly legitimate power with rational persuasion

Leadership Styles
Ray Gilmartin displays Transformational Leadership style which means he inspires followers to transcend their self-interest for the good of the organization:
• Idealized influence
• Inspirational Motivation
• Intellectual Stimulation
• Individualized Consideration

Bases of Power: Referent power with inspirational tactics

Root Causes
1. Overly hierarchical functional organizational structure.
2. Deficient integration of contributions between MRL and marketing.
3. Defender strategy is incompatible with the uncertain environment.

Proposed Solutions
The main barrier to Merck’s success through the 1990’s and into the 2000’s was the divide between MRL and Human Health marketing and sales departments. They exhibited inabilities to communicate and incompatibilities in collaboration in an uncertain and changing environment.
Their organization had outgrown their organizational structure and to maintain their innovative development of new drugs and their market-share
Merck needed a company-wide change.
MRL would need to create marketable drugs and the marketing department would need to be more innovative in their approach. These are not exclusive ailments, but rather symptoms of a larger issue. If a large scale systems approach is taken, Merck may see an increase in sales, stock-return, patent approvals, customer retention and health, employee morale, further global expansion, and corporate longevity.

Solution 1: Improvement of Communication & WBSTs
While WBSTs do serve to bridge the gap between MRL, manufacturing, and marketing, they still face structural challenges that lead to uneven results.
The fact that their members do not always have the proper authority to address the issues is one of the biggest hurdles on the MRL side. Sometime
WBSTs would have to discuss issues with three or four layers of MRL management to get the resources needed to solve the problem.
Cross functional information systems provide opportunities for coordination and collaboration groups and help to achieve unity of effort. To eliminate the hierarchical struggle within the WBSTs, the team members need direct reporting relationships between franchise heads and the president of MRL, similar to the communication structure on the marketing side.

Solution 1 (cont’d)
Accountability is a second big issue within WBSTs since they were initially added on to current responsibilities and viewed as a sideline task. In 2002,
Ray Gilmartin enacted performance grids to start holding WBST members more accountable for their work on the team. A follow-up assessment of those performance grid should be made to ensure accountability. Full-time integrator positions, such as therapeutic franchise managers, should also be created for each WBST to ease communication and manage accountability follow-up. Merck also needs to expand the PACE concept and establish a framework for best practices across the global enterprise. This solution would incorporate adding boundary spanners and people in buffer positions which would help to streamline the needs of the WBSTs while integrating analytical tools and methods in the PACE process for better planning and forecasting.

Solution 2: Organizational Structure Switch
As Merck moves through their elaboration stage of the organizational life cycle, they continue to show symptoms of structural deficiency. With
WBSTs, Merck improved overall decision making, but they continued to fail at innovatively responding to the changing environment.
Merck needs to split their organizational structure into multiple divisions and follow a less bureaucratic structure in order to return to a small company philosophy, increase the level of interdepartmental coordination, and continue organic development. Introducing knowledge-based teams in each division would help to more quickly examine and resolve the emerging environmental market changes. Replacing the top managers when needed and following social control and self-discipline would reduce the need for additional formal controls.

Solution 2 (cont’d)
When the organization grows, the professional support group ratio also increases in proportion to organization size. Merck needs to cut the overhead costs by keeping administrative, clerical, and professional support staff low. Further reducing the bureaucracy by cutting layers of hierarchy,
Merck needs to streamline their corporate headquarters and give lower level workers greater freedom to make decisions.
Introducing formal training develops professionalism in staff which gives creativity to employees allowing them to solve problems more quickly. Merck would continue to evaluate the organization performance using market control mechanisms.

Solution 2 (cont’d)
Merck needs a team of people dedicated to overseeing each drug through the development process and a switch to the matrix structure with product managers. Solution 2 (cont’d)
S.M. Davis and P.R. Lawrence’s proposed conditions for the use of a Matrix
1. Insufficient personnel for each product line to have an exclusive team
2. Environmental need for in-depth technical expertise and the frequent development of new products
3. A complex and uncertain environmental domain.
These three conditions indicate vertical and horizontal lines of authority require equal and balanced power. A matrix structure will facilitate discussion and teamwork and swift adaptation to unexpected problems.

Solution 3: Outsourcing, Alliances, Acquisitions, & Mergers
In an era which values generics almost as much as brand name medicines and where drug sales are directly related to advertising dollars, a sciencefirst mission can no longer keep up with the uncertain environment.
Remodeling their traditional and expensive R&D operations would prove fiscally beneficial for Merck.
Taking advantage of a virtually integrated and outsourced R&D program would significantly reduce expenditures. Merck should also outsource noncore functions such as IT and human resources in order to focus on producing and marketing finished products.
These changes would require changing the strategic vision of Merck and partnering with other companies to maintain growth.

Solution 3 (cont’d)
Simultaneously, Merck should cut down their manufacturing units by 25% and seek strategic alliances with major drug manufacturing organizations in low cost destinations to maximize short and long term revenues.
Merck should partner with these competitors, license each drug, and enter into critical multinational marketing segments to open up broader opportunities in the target industry. This type of alliance also increases the customer base. Acquiring other small companies, merging with other industry leaders, and forming an international conglomerate would allow
Merck to expand its product line and its reach into international markets.

Our Recommendations
After changing leadership, instituting the PACE process, and adding WBSTs, Gilmartin asked,

“What actions should we take at this point? Have we gone far enough? How far can we progress and still preserve Merck’s distinctive science-led culture?”

Our Recommendations (cont’d)
Above all Merck wanted to maintain their scientific reputation, but also wanted to see an improvement in their stock performance and show they were ready to adapt to future changes. Before the highly uncertain environment pushes
Merck out, they need to complete an offensive structure switch that will allow them to thrive under any condition.
We believe Merck should take a strong restructuring approach and use our second proposed solution. The key to the success of the proposed matrix structural change is working together along both functional and divisional lines.

Our Recommendations (cont’d)
The matrix structure switch requires
• Significant training for upper-level associates to implement these complex changes. o They specifically will need to work on developing skills to share power and facilitate communication across the dueling chains of command.
• For the plan to succeed, all staff will need to continue professional training to work on developing their problem solving creativity and flexibility to work in a nontraditional environment.

Our Recommendations (cont’d)
Once implemented, the structural change will have reduced the hierarchy, fully integrated the product development process across
MRL, manufacturing, and marketing, and redirected the company into an analyzer strategy better preparing Merck for the future.

...what would you do?

Thank you!
We look forward to your comments.

Similar Documents

Premium Essay

Merck Case Question

...Questions for the Merck Case Create a decision tree for Merck. The 2 leftmost branches would identify the alternatives related to licensing Davarink (specifically license versus not to license). Next, if Merck decides to pursue license, they go into phase I which results in a success, or failure. Phase I success is followed by phase II where Merck has the opportunity to develop the drug to treat depression alone, weight loss alone, or both, or contemplate phase II failure. Finally phase II success for different options leads to phase III, and there are success or failure related outcomes for each of the alternatives in phase II (i.e. developing the drug to treat depression, weight loss, or both). HINTS: Within each phase, remember that the probabilities of various outcomes (including failure, which is not always mentioned as an option) should add up to 100%. In each phase, the stated cost already includes fees paid to LAB. For example, cost of Phase I is $30 million (this number includes $5 million paid to LAB). A careful read of the case is critical to get the tree, various probabilities and the cash flows right. Please be sure to include your decision tree along with your answer to the questions below. 1) What is the expected value in launching Davarink as an antidepressant only? 2) What is the expected value in launching Davarink to treat only weight loss? 3) What is the expected value in launching Davarink for possibility of separate...

Words: 423 - Pages: 2

Free Essay

Case Study Merck Acquisition

...Case FIN561: Mergers and Acquisitions You decide: Merck Acquition of Medco Vikash Sharma In July 1993, Merck & Co., the largest pharmaceutical company in the world at that time, acquired Medco Containment Services for $6.6 billion. Medco was the largest prescription benefits management company. With the drug industry experiencing the effects of managed care, pharmaceutical companies had to adapt to new means of distribution. Merck realized that the decisions of what treatments and what drugs should be used in patients’ care were increasingly being influenced by the managed care environment rather than by physicians. In the world of managed care, it was no longer sufficient to market just to physicians. The successful pharmaceutical companies of the future would be companies that were able to adapt to the changed distribution system. This was a very strategic move my Merck and this vertical integration was a move that all its competitors were also targeting. In 1994 SmithKline acquired DPS for $2.2B and later that year Eli Lily acquired PCS for $4.1B. In order to understand why Merck acquired Medco, which was a pharmacy benefits management (PBM) company, we need to look at the role of this so-called PBM’s. These PBM’s have several functions * Process Pharmacy claims i.e. check for eligibility when an order is placed at the retail store, check for copayment etc * Set up Pharmacy benefit, which is to apply PBM codes to what drugs are covered under a......

Words: 973 - Pages: 4

Premium Essay

Merck Case Analysis

...Stakeholder Analysis – Merck Identify Key Stakeholders In the pharmaceutical industry, there is much to consider and constantly change in order to continue profits. In order to continue profits, a main factor, as said by former Merck president George W Merck, is the people. Merck said, “We try to never forget that medicine is for the people”. The first group of stakeholders has to be the people, or the consumer. The consumer is actually using the product from Merck and Co. and ultimately determines the success of the business. The second group of stakeholders is the employees. Employees determine the performance of the company. The employees consist of the executives and the lower management. A third group is the research and developers. A new drug must be created in order for the company to succeed. Ray Gilmartin, CEO, invests millions to create new drugs for Merck. One important example is the race to create one’s own Cox-2-inhibiting painkiller. A fourth group of key stakeholders is the doctors. Sales representatives try to sell Merck’s product to doctor’s offices. $102 million was spent just on sales representatives. Successful sales representatives lead to doctors writing prescriptions to patients for Merck’s products. Lastly, investors are a key stakeholder. An investor in the business cares about the downfalls and upcoming of a company because it is their money. The investor wants to receive a return on their initial investment and for the company to do......

Words: 600 - Pages: 3

Premium Essay


...Introduction Merck was established in the U.S. in 1891, but its roots trace back to Friedrich Jacob Merck’s purchase of a German drug store in 1668. Today the company is a top tier global entity, a “research-driven” pharmaceutical company “dedicated to putting patients first.” Merck’s mission is to “provide society with superior products that improve the quality of life and satisfy customer needs, provide employees with meaningful work and investors with a superior rate of return.” As a long time player in the U.S. pharmaceutical industry, Merck has had extensive experience in assigning and dividing complex tasks among its many specialized departments. Specialization allows Merck to operate efficiently and bring new drugs to American patients. On May 20, 1999, the FDA approved Merck’s application to market Vioxx, a new arthritis pain-reliever. The effort to create a successful drug at Merck was no small task, not only did the company need to develop, test, and receive approval for a new product. It also needed to make sure the drug was successfully marketed to the right consumers. By the end of 1999, over 5 million prescriptions had been written for Vioxx and it had been launched in 47 countries. The Vioxx launch went particularly well, and Merck splashed its success across the front page of its Annual Report with the lead, “Vioxx: Our biggest, fastest and best launch ever.” New Vioxx sales came at an important time for Merck. The exclusive patents to four major drugs......

Words: 492 - Pages: 2

Free Essay

Merck Case Study

...Εισαγωγή Η αρχή της δεκαετίας του 1990 αποτέλεσε για τις φαρμακευτικές βιομηχανίες το χρονικό ορόσημο, όπου άλλαξαν δραματικά τα δεδομένα ανάπτυξης και κερδοφορίας για το συγκεκριμένο χώρο σε παγκόσμιο επίπεδο. Έτσι παρατηρήθηκαν, σημαντικές μειώσεις στις πωλήσεις φαρμάκων και συνεπώς των κερδών, καθώς και πολύ μεγάλες πτώσεις στις τιμές των μετοχών των εταιρειών που δραστηριοποιούνταν στο συγκεκριμένο αντικείμενο. Μία από τις κυρίαρχες εταιρείες του χώρου των φαρμάκων η οποία επηρεάστηκε σημαντικά από τις εξελίξεις της δεκαετίας ήταν η Merck. Αν συλλογιστεί κανείς ότι ο συγκεκριμένος κλάδος προερχόταν από μία περίοδο τεράστιας άνθισης της κερδοφορίας (πριν το 1990), αξίζει να γίνει μία ανάλυση των αιτιών που οδήγησαν σε αυτήν την αρνητική μεταστροφή διερευνώντας τόσο το εξωτερικό όσο και το εσωτερικό περιβάλλον της εταιρείας. Προκλήσεις εταιρείας Αναλύοντας το εξωτερικό μακροπεριβάλλον, θα πρέπει να σταθεί κανείς στη νομοθετική ρύθμιση των Waxman-Hatch (1984) στις Η.Π.Α. κατά την οποία μειώθηκαν ουσιαστικά τα εμπόδια εισόδου των γενοσήμων φαρμάκων (generics) στην αγορά. Με τη νομοθετική αυτή ρύθμιση, επιταγχύνθηκαν δραστικά οι διαδικασίες εγκρίσεων των φαρμάκων αυτού του τύπου, καθώς δεν απαιτούνταν πλέον χημικοί και βιολογικοί έλεγχοι προκειμένου να κυκλοφορήσουν στην αγορά. Έτσι, οι εταιρείες παρασκευής των γενοσήμων φαρμάκων, απουσία των κλινικών δοκιμών αλλά και των δαπανών για την έρευνα καθώς πρόκειται για αντιγραφές φαρμάκων, είχαν σημαντικές μειώσεις στα......

Words: 237 - Pages: 1

Free Essay


...Yes, Merck should develop Mectizan Intangible Gains: Merck would benefit from many intangible features by associating its brand with such sensitive public cause. Consumers: The initiative of distributing the drug for free would position Merck in the top of mind for consumers since the company is seen not anymore as a “just-for-profit” company but actually an organization that is really committed in improving the healthy of the people around the world. Consumers are also benefited by the fact that competitors may try to imitate Merck and similar initiatives may be deployed in the future. This program also helps to set up new and better standards for public health campaigns. Public Relations: It is important to highlight that although this program would run in Africa, where the consumer market in terms or revenues is not as big as in the developed countries, this program was able to generate huge traction among several important media companies around the world and millions of people would be “impacted” by the program features. Competitors: another intangible benefit for Merck is that this program helps the company to distinguish itself from the other big multinational pharmaceutical companies, leveraging also the relationship with suppliers and clients due to this uniqueness. It also signalize to competitors that Merck has very “deep pockets” for sustaining such a program and this may deter the competitors of entering in markets / products where Merck is......

Words: 510 - Pages: 3

Premium Essay


...9-201-023 REV: MARCH 25, 2003 RICHARD S. RUBACK Merck & Company: Evaluating a Drug Licensing Opportunity Rich Kender, Vice President of Financial Evaluation & Analysis at Merck, was working with his team to decide whether his company should license Davanrik, a new drug with the potential to treat both depression and obesity. The small pharmaceutical concern that developed the drug, LAB Pharmaceuticals, lacked the resources to complete the lengthy approval process, manufacture the compound, and market the drug. LAB had approached Merck with an offer to license the compound. Under this agreement, Merck would be responsible for the approval of Davanrik, its manufacture, and its marketing. The company would pay LAB an initial fee, a royalty on all sales, and make additional payments as Davanrik completed each stage of the approval process. Merck In 2000, Merck & Co., Inc. was a global research-driven pharmaceutical company that discovers, develops, manufactures and markets a broad range of human and animal health products, directly and through its joint ventures, and provides pharmaceutical benefit management services (PBM) through Merck-Medco Managed Care. Since 1995, Merck had launched 15 new products including Vioxx™ for the treatment of osteoarthritis, Fosamax™ for the treatment of osteoporosis and Singulair™ for treating asthma. The Company earned $5.9 billion on 1999 sales1 of $32.7 billion, about a 20% increase from 1998. Exhibits 1 and 2 contain Merck’s Income...

Words: 2360 - Pages: 10

Free Essay

Merck Case Study

...Merck & Costa Rica Case Study Rory S Smith Ethics in Global Environment State University of New York Empire State College Introduction Companies globally are often times scrutinize for their business practices. They face strong opposition and public humiliation when they conduct their business in an unethical way. When companies operate globally, they must ensure they are operating in a socially responsible manner. Being socially responsible is not just giving back to the local community but to be aware of any unforeseen threats that may affect the business. Many countries around the world do not have strict laws governing the preservation of their natural resources. Global companies see this to their advantage to reap the natural resources and leaving back not an ounce of guilt, for a country’s social and economic instability caused by their actions. Industries like manufacturing, pharmaceutical and oil refinery, many corporations contribute to the injustice of violating human rights and the environment. As the business world and economy evolves into a free market enterprise, many corporations continue to demonstrate poor business practices and it is becoming difficult to hold them liable for their actions. Many corporations are also being very silent about their unjust business practices and have many ways to cover up any reported abuse. Countries that experience environmental violations, should impose strict regulatory policies so......

Words: 2141 - Pages: 9

Free Essay

Merck Case

...que repercutió en el desplome del rendimiento de activos de dicha empresa, hasta antes de la conformación de un comité de estudio para mejorar resolver dicha problemática en el año de 1985. Merck & Co., es una farmacéutica que tuvo sus inicios en Alemania en 1668; en el año de 1887 apertura su sucursal en la ciudad de New York, Estados Unidos; en primera instancia para comercializar los productos alemanes, posterior a ello se dedicó a fabricar medicamentos y productos químicos que hasta la actualidad gozan de fama y prestigio. Merck & Co., ocupó titulares de renombre y gozó de prestigiosos premios, además de la fama que incluían su solidez financiera, calidad en sus productos, innovación, y capacidad para desarrollar talento de su personal, su rentabilidad era superior a las otras corporaciones de su medio. Sin embargo y pese al éxito, en 1983 Merck & Co., empezó a experimentar un declive en sus activos, el rendimiento de la misma quedó rezagada en esa fecha, debido a varios factores económicos del medio, y del descontento existente entre el personal debido a la aplicación no adecuada del sistema de medición del desempeño por ende de las recompensas. Introdujo por primera vez en 1978 el programa de administración de salarios y evaluación del desempeño de Merck, en el que los supervisores evaluaban en una escala del 1 al 5 a sus empleados, designando al 1 como rendimiento inaceptable y 5 como rendimiento excepcional. La escala era absoluta y la......

Words: 1532 - Pages: 7

Free Essay

Merck Case

...suffering from the disease or those who potentially may be infected – would directly benefit from the cure Merck employees at all levels – profitability and the economic health of the company affects current employees Merck shareholders – inability to profit from the drug might have a negative effect on shareholder’s value, but taking the stand on “doing the right thing” might have a favorable effect on company’s reputation and increase the value of the stock Various healthcare organizations – Merck is one of the leaders in the industry whose actions or inactions may affect the state of the industry as a whole One way to rank stakeholders in importance is by their level of benefit from the drug putting people suffering from the disease in the first place as they would benefit the most from the invent of the cure. Then, employees and shareholders would share the second place, provided that the company would most likely not be able to recover funds invested in the long and expensive process of developing the drug which in turn would affect company’s profitability. Finally, various healthcare organizations would rank third; the effect on them would depend on the level of their involvement in the process. 2. What are the potential costs and benefits of such an investment? Developing a drug to combat river blindness has substantial potential costs and befits. Merck discovered an opportunity to treat millions of affected people around the world but it knew that the......

Words: 321 - Pages: 2

Premium Essay

Merck Case Study

...Case Study: Merck Acquisition of Medco Professor Daniel Weiss FI561 January 23, 2011 DeVry University Case Study: Merck Acquisition of Medco Abstract The purpose of this case study is to determine whether it would be beneficial to merge Merck Corporation with Medco Containment Services Incorporated. The merger and acquisition between the world’s largest drug manufacturer and the largest prescription benefits management company (PBM) and marketer of mail order medicines in the United States would result in a successful campaign to take over the drug industry if handled appropriately. As Chairman and CEO of Merck Corporation, I have to consider all sides of the arguments, financially, marketing and cultural wise and come to a conclusion as to whether this merger would be a good idea for the company. Like any other investment and merger, there are risks, and I have to decide what would be best in the interest of this company. The details as to whether the decision to acquire or not acquire Medco will be described in this paper. Along with data that helps make that final decision. There are a few things one must take into account before making a decision. You have to look at the long term run, whether or not the merger and acquisition will be successful. You also have to take synergy into account; it is the most important reason why there are a lot of mergers and acquisitions. Synergy would be when two companies join forces to create additional value and cut......

Words: 2468 - Pages: 10

Premium Essay

Merck Case Solution

...Protect Veterinary Business Merck Should Develop Companies do not justify every investment to shareholders, so we are not convinced that they would need to justify this one. But, they certainly would not be able to justify it in terms of the financial bottom line. They would have to justify it in terms of goodwill, or some other more difficult to measure criterion. Cost of development of human drug is less as when they had to find for new drug That if other organizations decided to go on their own and produce and distribute Mectizan without Merck, the cost of production would be significantly higher for them than for Merck due to the need to invest in production facilities. To be conservative, we assume that their cost savings in distribution are cancelled out due to the excess costs in production and therefore they have the same total cost as Merck. By running this program, Merck also do benefit from many intangible features by associating its brand with such sensitive public cause. Among these intangible benefits there are: Public Relations: It is important to highlight that although this program was run in Africa, where the consumer market in terms or revenues is not as big as in the developed countries, this program was able to generate huge traction among several important media companies around the world and millions of people were "impacted" by the program features. Although it is hard to quantify, there is no doubt that Merck brand equity was leveraged......

Words: 776 - Pages: 4

Premium Essay


...3. Should Merck bid to license Davanrik? How much should they pay? Our team will recommend Merck bid to license Davanrik given the following reasons: 1. One of the major advantage of the company is its patents of new drugs. According to the case, we know that four drugs will expire by 2002 and those drugs are regarded as the so-called star-products of the company. According to the company’s financial statement, we learn that Merck’s net income margin has declined from 19.52% to 18% and the research and development cost has been decreased in terms of percentage of sales. So we believe that Merck should increase its expenditure on research. On the expiration of the drugs, the sales will decreased dramatically as competition emerges. So in order to maintain its competition edge, the company need to develop new drugs. 2. Even though the company used to develop new compounds primarily through internal research, we believe that working with LAB Pharmaceuticals will give Merck a synergy effect to obtain a better result. Given LAB Pharmaceuticals’ performance in the past, we believe that Merck’s plentiful experience will sure to make to most of the pre-clinical development of Davanrik. 3. According to the balance sheet, we can learn that Merck has sufficient cash to support the licensing process and we believe the company has the ability to absorb the potential loss on failure. So the risk is tolerable for Merck. So we will suggest Merck bid to license Davanrik. As for the bid...

Words: 545 - Pages: 3

Premium Essay

Merck and Lab Pharmaceuticals Case Study

...Business description In 2000 Merck is a successful pharmaceutical company with a handful of drugs developed internally as well as in joint-ventures. Its success however linked to the exclusivity rights of its patents, which makes its investors concerned about the close expiration (2002) of several patents of its blockbusters, which would dry out future revenues. The long-term viability of the company depends thus on the ability to refresh its portfolio of patent-protected drugs in order to counterbalance the loss of sales resulting from the generics. The large financial capacity of Merck & Co enables the company to buy rights to test, manufacture and market compounds which were generated by smaller companies which lack the capital or want to avoid the risk; in case the FDA is successfully completed Merck & Co. profits by having bought the patent at a cheap price. In this context a young pharma company, LAB Pharmaceuticals has approached Merck offering them to license one of their compounds called Davanrik. The company is in an uncomfortable financial situation and hesitates to launch the testing of this promising Davanrik, a drug whose use could be dual for weight and depression problems. Davanrik has already successfully completed the preclinical testing and has to complete the approval phases 1 to 3 and the final FDA approval. LAB proposed to Merck to be in charge of the approval of Davanrik, its manufacture and its marketing and would in exchange pay to LAB an initial fee,...

Words: 1029 - Pages: 5

Premium Essay

Merck Case - Business Ethic

...Vagelos as CEO and for Merck as a company in deciding whether to invest in Dr. Campbell’s idea? The stakes for Roy Vagelos as CEO would be the high level of risk to succeed, the strong change to have a low level of profitability even after the success, and the advantage of Dr Campbell’s project, less investment needed and government aid in tax. And the stakes for Merck as a company would be the corporate ethic it has pursued and Merck’s need to develop another new successful prescription. Q2. How does Merck pick from among the many ways to “do good” and many drugs to invest in? Merck took 12 years and $200 million to bring a new drug to market on the average. And thousands of scientists worked on new ideas and following new leads. It uses various methods to choose the project through extensive review and analysis on the basis of the likelihood of success, the existing market, competition, potential safety problems, manufacturing feasibility and patent. Q3. How much of its research budget should Merck invest in drugs that will likely produce a substandard return on its investment? The research budget should be considered in research/development expenses, expected income with the tax benefit from the government, and mostly the effect and impact based on the corporate ethics and morale. Q4. What should Merck tell a shareholder who might complain about a decision to invest in research on river blindness? The overall corporate philosophy of Merck is based on......

Words: 336 - Pages: 2